GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal …

– Primary endpoint achieved in both Epidiolex doses with high statistical significance compared to placebo – 

– Today’s data represents the third positive Phase 3 pivotal trial for Epidiolex reported in 2016 –

– Data reinforce the potential of Epidiolex to be an important new medicine for patients who suffer from this treatment-resistant childhood-onset epilepsy –  

– Company to hold investor conference call today at 8:00 a.m. EDT/13:00 BST –

LONDON, Sept. 26, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. In this trial,

... read more at: http://globenewswire.com/news-release/2016/09/26/874464/0/en/GW-Pharmaceuticals-Announces-Second-Positive-Phase-3-Pivotal-Trial-for-Epidiolex-cannabidiol-in-the-Treatment-of-Lennox-Gastaut-Syndrome.html

by